Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
51
Active, not recruiting, industry sponsors, Infectious disease and vaccines, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,856
51 trials
Showing 1 to 25, recently updated first.
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02362503 · 371 participants · Start Feb 23, 2015 · Primary completion Aug 18, 2016
Drug: BMS-663068 · For: HIV Infections
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 139 sites in all
- A Study of COVID-19 Vaccine(s) in Children and AdultsPivotal-lookingActive, not recruiting
BioNTech SEIndustry
NCT07798648 · 713 participants · Start Aug 31, 2026 · Primary completion Apr 12, 2027
Drug: BNT162b2; BNT162b2 and 1 more · For: COVID-19 Vaccines
Sites: Homestead, Florida; Miami Lakes, Florida; Atlanta, Georgia · 15 sites in all
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)Pivotal-lookingActive, not recruiting
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT07711223 · 660 participants (planned) · Start Nov 7, 2025 · Primary completion Aug 31, 2028
Drug: ACC017+FTC/TAF; DTG+FTC/TAF · For: Infection, Human Immunodeficiency Virus
Sites: Beijing, China
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05889182 · 1,328 participants (planned) · Start Jun 21, 2023 · Primary completion Aug 2028
Drug: Upadacitinib; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fountain Hills, Arizona; Phoenix, Arizona · 285 sites in all
- A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07794748 · 4,701 participants · Start Sep 8, 2026 · Primary completion Apr 26, 2027
Drug: PG4 Multivalent Vaccine; PG4 Multivalent Vaccine and 2 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Lake Forest, California; Walnut Creek, California · 37 sites in all
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06959225 · 580 participants · Start Jun 23, 2025 · Primary completion Oct 29, 2026
Drug: Ruxolitinib Cream; Vehicle Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 101 sites in all
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06694805 · 326 participants · Start Dec 2, 2024 · Primary completion Aug 19, 2026
Drug: CAB LA + RPV LA; Oral ART · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 85 sites in all
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02951052 · 618 participants · Start Oct 28, 2016 · Primary completion May 29, 2018
Drug: Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet and 3 more · For: Infection, Human Immunodeficiency Virus; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 113 sites in all
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06958211 · 573 participants · Start Jun 12, 2025 · Primary completion Oct 1, 2026
Drug: Ruxolitinib Cream; Vehicle Cream · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 107 sites in all
- A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseasePivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07220109 · 750 participants · Start Oct 29, 2025 · Primary completion Jul 20, 2026
Drug: RSVPreF3 OA vaccine; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Beijing, China; Xiangtan, China; Nanjing, China · 15 sites in all
- Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06134362 · 2,998 participants · Start May 14, 2024 · Primary completion Mar 14, 2029
Drug: CAB LA · For: HIV Infections
Sites: Almagro, Argentina; Buenos Aires, Argentina; Francistown, Botswana · 33 sites in all
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT03299049 · 1,049 participants · Start Oct 27, 2017 · Primary completion Jun 6, 2019
Drug: Cabotegravir Tablets; Rilpivirine Tablets and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 119 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06799000 · 588 participants · Start Jan 31, 2025 · Primary completion May 17, 2027
Drug: Remibrutinib Dose A; Remibrutinib Dose B and 2 more · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fort Smith, Arkansas; North Little Rock, Arkansas · 139 sites in all
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06840392 · 565 participants · Start Mar 20, 2025 · Primary completion Jun 3, 2027
Drug: Remibrutinib Dose A; Remibrutinib Dose B and 2 more · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Gilbert, Arizona; Fremont, California · 129 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT05979311 · 463 participants · Start Feb 21, 2024 · Primary completion Apr 15, 2026
Drug: Dolutegravir; Lamivudine and 3 more · For: HIV; HIV Infections
Sites: Ciudad Autonoma de Buenos Aire, Argentina; Córdoba, Argentina; Brussels, Belgium · 64 sites in all
- A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07287644 · 210 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 1, 2027
Drug: BFB759 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 64 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04925752 · 3,292 participants · Start Jun 28, 2021 · Primary completion Aug 21, 2024
Drug: Oral Lenacapavir (LEN); F/TDF and 5 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 93 sites in all
- LMN-201 for Prevention of C. Difficile Infection RecurrencePivotal-lookingActive, not recruiting
Lumen Bioscience, Inc.Industry
NCT05330182 · 375 participants (planned) · Start Aug 29, 2024 · Primary completion Aug 31, 2026
Drug: LMN-201; Placebo · For: Clostridioides Difficile Infection
Sites: Escondido, California; Hamden, Connecticut; Tampa, Florida · 15 sites in all
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06534892 · 10,212 participants · Start Aug 1, 2024 · Primary completion Sep 30, 2026
Drug: RSVPreF3 OA vaccine · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 251 sites in all
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AbovePivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04732871 · 1,720 participants · Start Feb 15, 2021 · Primary completion Jun 6, 2022
Drug: RSVPreF3 OA investigational vaccine · For: Respiratory Syncytial Virus Infections
Sites: Mobile, Alabama; Phoenix, Arizona; Riverside, California · 46 sites in all
- A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
NCT06921850 · 43 participants · Start Apr 7, 2025 · Primary completion Dec 21, 2026
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Roseville, California; Sacramento, California; Washington D.C., District of Columbia · 16 sites in all
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07044297 · 4,390 participants · Start Jul 31, 2025 · Primary completion Jul 22, 2027
Drug: MK-8527; FTC/TDF and 2 more · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Sites: Birmingham, Alabama; Mobile, Alabama; Los Angeles, California · 81 sites in all
- A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07596199 · 102 participants · Start Jun 29, 2026 · Primary completion Nov 23, 2026
Drug: dTpa · For: Diphtheria-Tetanus-acellular Pertussis Vaccines
Sites: Aichi, Japan; Chiba, Japan; Fukui, Japan · 21 sites in all
- A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesPivotal-lookingActive, not recruiting
LG ChemIndustry
NCT06947499 · 1,186 participants (planned) · Start May 30, 2025 · Primary completion Feb 28, 2028
Drug: LBVD; Pentavalent vaccine and Inactivated Polio vaccine · For: Diphtheria; Tetanus; Pertussis and 3 more
Sites: Dasmariñas, Philippines
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.